Epitope Incorporation within Adenovirus Type 3 Hexon

Protection against Enterovirus 71 with Neutralizing Epitope Incorporation within Adenovirus Type 3 Hexon

Xingui Tian, Xiaobo Su, Xiao Li, Haitao Li, Ting Li, Zhichao Zhou, Tianhua Zhong, Rong Zhou

State Key Lab of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China

Abstract

Enterovirus 71 (EV71) is responsible for hand, foot and mouth disease with high mortality among children. Various neutralizing B cell epitopes of EV71 have been identified as potential vaccine candidates. Capsid-incorporation of antigens into adenovirus (Ad) has been developed for a novel vaccine approach. We constructed Ad3-based EV71 vaccine vectors by incorporating a neutralizing epitope SP70 containing 15 amino acids derived from capsid protein VP1 of EV71 within the different surface-exposed domains of the capsid protein hexon of Ad3EGFP, a recombinant adenovirus type 3 (Ad3) expressing enhanced green fluorescence protein. Thermostability and growth kinetic assays suggested that the SP70 epitope incorporation into hypervariable region (HVR1, HVR2, or HVR7) of the hexon did not affect Ad fitness. The SP70 epitopes were thought to be exposed on all hexon-modified intact virion surfaces. Repeated administration of BALB/c mice with the modified Ads resulted in boosting of the anti-SP70 humoral immune response. Importantly, the modified Ads immunization of mother mice conferred protection in vivo to neonatal mice against the lethal EV71 challenge, and the modified Ads-immunized mice serum also conferred passive protection against the lethal challenge in newborn mice. Compared with the recombinant GST-fused SP70 protein immunization, immunization with the Ads containing SP70 in HVR1 or HVR2 elicited higher SP70-specific IgG titers, higher neutralization titers, and conferred more effective protection to neonatal mice. Thus, this study provides valuable information for hexon-modified Ad3 vector development as a promising EV71 vaccine candidate and as an epitope-delivering vehicle for other pathogens.

Introduction

Enterovirus 71 (EV71) is the most frequently detected pathogen in hand, foot and mouth disease (HFMD) patients complicated with the severest forms of neurological disorders [1,2,3]. Outbreaks of EV71 have been reported around the world since 1969. Especially since the late 1990s, there has been a significant increase in EV71 epidemics, and it has emerged as a serious threat to public health throughout the Asia-Pacific region [4,5,6,7]. However, there are no effective antiviral drugs and vaccines presently available. The development of effective vaccines is a top priority in terms of control strategies [8]. EV71 is a small, non-enveloped, positive single-stranded RNA virus with four capsid proteins: VP1, VP2, VP3 and VP4. The neutralizing antibodies elicited by SP70 epitope containing amino acids 208–222 of VP1 protein were able to confer good in vivo passive protection against homologous and heterologous EV71 strains in suckling BALB/c mice [9,10,11]. Therefore, the epitope-based vaccine represents a promising candidate for EV71.

Epitope-based vaccination is one area under intense investigation for the delivery of precise vaccine components to the immune system. The peptide epitope represents the minimal immunogenic region of a protein antigen and allows exquisite direction and control of immune responses [12]. However, there are some drawbacks including poor immunogenicity of the simple peptide and the need to potently stimulate T cells and elicit immunological memory. Although some approaches, such as adjuvant science, lipopeptide conjugation, direct delivery to dendritic cells, and particulate delivery systems have been developed, novel and powerful methods for efficiently delivering epitopes are still needed [12,13,14].

Adenovirus (Ad), especially Ad serotype 5 (Ad5) vectors, have been successfully used for a variety of vaccine applications, including cancer and infectious diseases [15,16,17,18]. Recently a novel approach is developed to incorporate antigenic epitopes into the Ad capsid proteins: hexon, fiber knob, and penton base, as well as protein IX [19,20,21,22]. Incorporating immunogenic peptides into the Ad capsid offers potential advantages: a strong humoral response similar to the response generated by native Ad capsid proteins, allowing boosting of the immune response against antigenic epitopes that are part of the Ad capsid [18]. Hexon is the largest and most abundant capsid protein. Although several groups have shown that short heterologous peptides can be incorporated into the Ad5 hexon without affecting the virion’s stability or function [19,22,23,24,25], hexon modification often results in failure of rescuing viruses or poorly growing viruses,
suggested, hexon modification may interfere with viral formation [24,26,27]. The immune response against an epitope inserted into Ad5 hexon is dependent on the incorporation site and sometimes not satisfying [28]. So it is necessary to develop non-Ad5 vector as an epitope-delivering system.

Here we reported a novel epitope-delivering system based Ad3. An Ad3 vector, a member of species B adenoviruses, has been developed previously as a candidate for vaccine design and gene transfer [29]. Ad3-based vectors are relatively safe as compared to Ad5 [30]. Unlike members of other adenovirus species that bind to the cell surface receptor CAR, members of species B recognize the membrane co-factor proteins CD46, CD80, and CD86 as cellular receptors [31,32]. In this study, we investigated whether foreign peptides could be incorporated into different surface-exposed domains of the Ad3 hexon without affecting the normal function and whether they could elicit effective immune responses. We developed an epitope-based vaccine against EV71 by incorporating the foreign epitope EV71-derived SP70 containing 15 amino acids within the Ad3 hexon. Our study provides valuable information for the development of Ad3-based vaccine delivering epitopes from pathogens or cancer cells by hexon-incorporation.

Results

Construction of Hexon-modified Ad3 Containing EV71 Epitope

The hexon-modified plasmids, pR1SP70A3egf, pR2SP70A3egf, pr4SP70A3egf, pR5SP70A3egf, pR7SP70A3egf were obtained by homologous recombination and confirmed by restriction enzyme digestions and full length hexon sequencing analysis (data not shown). In the case of R1SP70A3, R2SP70A3, and R7SP70A3, the replacement of epitopes resulted in viable viruses. The fluorescence focus did spread from individual cells transfectected with the plasmid, however, R1SP70A3 grew much more slowly than did the other viruses, and repeated attempts to amplify and purify the virion by CsCl centrifugation were unsuccessful. In cells transfected with the plasmid, no evidence of virus growth was seen even at 14 days post-transfection. So the viruses of R1SP70A3, R2SP70A3, and R7SP70A3 were chosen for further characterization. The hexon modification of viruses of R1SP70A3, R2SP70A3, and R7SP70A3 were confirmed by PCR and sequencing using genomic DNA from the purified virions (Fig. 1A). In order to determine the hexon-modified vectors were presenting the SP70 epitope within the hexon region, purified R1SP70A3, R2SP70A3, and R7SP70A3, or unmodified Ad3EGFP were subjected to Western blot analysis with anti-SP70-GST antibody. The SP70 peptide was detected as an approximately 120 kDa protein band associated with R1SP70A3, R2SP70A3, R7SP70A3 particles (Fig. 1B, lanes 3, 4, and 5, respectively). The size of the 120 kDa band corresponded to the expected size of the Ad3 hexon protein with SP70 peptide genetically incorporated. There was no band detected on Ad3EGFP particles (Fig. 1B, lane 2), HEp-2 cells or Vero cells as negative controls (data not shown). In the case of R1SP70A3, R2SP70A3, and R7SP70A3, the replacement of epitopes resulted in viable viruses.

To determine whether the SP70 epitope was presented on the virion surface, different amount of purified virions were subjected to ELISA with anti-SP70-GST antibody. As predicted, the anti-SP70-GST antibody bound to the R1SP70A3, R2SP70A3, whereas no binding was seen in response to the unmodified Ad3EGFP (Fig. 2A). The growth curves demonstrated that the hexon-modified viruses replicated with similar kinetics with unmodified Ad3EGFP (Fig. 2B). We also examined the efficiency of gene transfer for the hexon-modified viruses in HEp-2 cells with the aid of the EGFP reporter. There was no apparent difference between the modified viruses and the unmodified viruses, suggesting that the gene transfer ability was not significantly affected by hexon modification (Fig. 2C). These data suggested that the incorporation of SP70 epitope in HVR1, HVR2, or HVR7 of hexon did not significantly affect Ad fitness.

Presentation of SP70 Epitope on Virion Surface

To access whether the SP70 epitope was presented on the surface of modified virion, different amount of purified virions were immobilized on the wells of ELISA plates and incubated with anti-SP70-GST antibody. The results showed significant binding of the anti-SP70-GST antibody to the R1SP70A3, R2SP70A3, R7SP70A3, whereas no binding was seen in response to Ad3EGFP (Fig. 3A). These results indicated that the SP70 epitope was properly exposed on the virion surface when incorporated within HVR1, HVR2, or HVR7. In order to determine the capability of the SP70-specific antibody to bind capsid-incorporated antigen in a dose-dependent manner, a dose-response ELISA assay was performed with anti-SP70-GST antibody. A single concentration of R1SP70A3, R2SP70A3, or R7SP70A3 was applied to ELISA plates, followed by the addition of serial dilutions of anti-SP70-GST antibody. As predicted, the anti-SP70-
GST antibody bound to all three modified virions in a dose dependent manner (Fig. 3B).

It was interesting to determine whether the anti-SP70-GST antibody could neutralize the modified rAds containing the SP70 epitopes. The SP70 peptide antiserum efficiently neutralized R1SP70A3, R2SP70A3, and R7SP70A3 with similar titers over 100-fold more than that against EV71 (Table 1).

In order to test whether hexon modification could affect neutralization by anti-Ad3 antibody, HEp-2 cells were infected with hexon-modified rAds in the presence of Ad3EGFP-specific mouse antiserum. Ad infection was monitored by measuring EGFP expression. Replacement of HVR1 with the SP70 epitope clearly made the R1SP70A3 partly resistive to anti-Ad3EGFP serum, whereas the modification of HVR2 or HVR7 had no effect (Table 1).

Anti-SP70 Antibodies Produced in Mice after Vaccination

To verify the immunizing potential of these vectors against EV71 we next sought to characterize the immune response to the peptide in mice. Equal numbers (5 x 10^5 VP) of the virions were used to immunize BALB/c mice. The sera were collected from mice at various days after priming and boosting (Fig. 4A). In order to evaluate the humoral responses qualitatively, Vero cells were infected with EV71-08-02 strain and purified SP70-GST protein were subjected to Western blot analysis with antiserum from mice immunized with R1SP70A3, R2SP70A3, R7SP70A3, or Ad3EGFP (Fig. 4B). Approximately 33 kDa protein bands associated with EV71 were detected with the antiserum from mice immunized with modified virions. The size of the 32.6 kDa band corresponded to the expected size of the EV71 VP1 protein containing SP70 epitope. There was no VP1 protein detected with antiserum immunized with unmodified virion Ad3EGFP. These results indicated that humoral immune responses had been elicited against the SP70 incorporated in hexon.

Levels of anti-SP70 total IgG in sera of immunized mice were quantified using indirect ELISAs (Fig. 4C). Synthetic SP70 peptide was bound to ELISA plates. The plates were then incubated with the immunized mice sera. As expected, no IgG against SP70 was present in preimmune sera. In sera collected from control Ad3EGFP-injected mice or GST-injected mice at any time, no anti-SP70 IgG was detectable. Immunization with synthesized SP70 peptide or control PBS repeatedly also did not induce significant anti-SP70 IgG titers. On the contrary, mice immunized with rAds that contained capsid-incorporated SP70 epitope had detectable levels of SP70-specific IgG at 2 weeks, which increased approximately after boosting. Mice injected with heat-inactivated EV71 strain and recombinant protein SP70-GST had no detectable anti-SP70 IgG at 2 weeks, but had detectable levels of SP70-specific IgG at 4 weeks. Anti-SP70 IgG levels were significantly higher in rAds-injected mice than in EV71-injected mice (P<0.05). Serum levels of anti-SP70 total IgG were also quantified by ELISAs using plates coated with recombinant peptide SP70-GST, and the results were similar to that using synthetic SP70 peptide (data not shown). In summary, R1SP70A3, R2SP70A3, and R7SP70A3 elicited strong anti-SP70 humoral responses in vaccinated mice which increased after boosting.

Isotype-specific anti-SP70 IgG antibodies were produced in mice after vaccination. Levels of anti-SP70 IgG subtypes, IgG1 and IgG2a, IgG2b, IgG2c, and IgG3 were also assessed in 5-week sera to determine the subtype of immune response being stimulated (Fig. 4D). The figure shows data of anti-EV71-08-02 sera diluted 1:1000 and other groups antiserum diluted 1:10000. In mice, IgG1 is indicative of a Th2-type response, whereas IgG2a and IgG2b are predominantly produced during a Th1 response. As expected, mice receiving Ad3EGFP had no detectable levels of all anti-SP70 subtypes (data not shown). All mice had no detectable levels of anti-SP70 IgG2C (data not shown). Mice injected with heat inactivated EV71 or hexon-modified rAds had detectable levels of IgG1, IgG2a, IgG2b, and IgG3. Mice injected with SP70-GST had detectable levels of IgG1, IgG2a, and IgG2b without detectable levels of IgG3. These data suggested that both Th1- and Th2-type responses had been stimulated. However, R1SP70A3 immunization led to higher levels of IgG2a (OD=0.97), but lower levels of IgG1 (OD=0.31) and IgG2b (OD=0.22). The R7SP70A3 and SP70-GST resulted in higher levels of IgG1 with lower levels of IgG2a and IgG2b. In contrast, the heat-inactivated EV71 and R2SP70A3 gave rise to relatively balanced levels of IgG1, IgG2a, and IgG2b.

The early IgM humoral responses against SP70 were assessed on day 7 after the first immunization. IgM titers increased two-fold in the sera of R1SP70A3 or R2SP70A3-immunized mice compared to those of mice immunized with R7SP70A3 (P<0.05), whereas for Ad3EGFP and PBS groups no SP70-specific IgM was detected (Fig. 4E).

Serum levels of anti-EGFP total IgG were also quantified using indirect ELISAs (Fig. 4F). After two injections, the transfer gene production EGFP-specific antibody responses were noticeably inhibited.

Cellular Immune Response to Recombinant Adenovirus

In this study we sought to determine if SP70 presented on the surface of adenovirus could be processed to activate specific cellular immunity. SP70-specific IL-4 and IFN-γ ELISPOT1 assays were performed on splenocytes of mice 5 days after the third injection (Fig. 5). In splenocytes obtained from heat-inactivated EV71 mice or rAds-immunized mice, no IL-4 or IFN-γ secreting cells were present above background levels after stimulation with SP70 peptide. In the case of rAds-immunized mice, IFN-γ-secreting cells were detected upon stimulation with EGFP proteins (P<0.05). These results suggested that SP70-specific cellular responses were not significantly induced.

Protection against Lethal EV71 Strain Challenge in Suckling Mice

To assess the efficacy of passive protection by antiserum raised against R1SP70A3, R2SP70A3, and R7SP70A3, suckling Balb/c mice born to naive dams were challenged with the EV71-08-02 strain (1000 TCID50 per mouse) administered with 20 μl of the respective antiserum. The titers of the respective antiserum
Figure 3. SP70 epitope incorporated in HVR1, HVR2, or HVR7 was exposed on the virion surface. (A) In the assay $5 \times 10^8$ VPs/well of R1SP70A3, R2SP70A3, R7SP70A3, or Ad3EGFP were adsorbed on ELISA plates followed by varying dilutions of SP70-GST antiserum. (B) Various amounts of purified virions R1SP70A3, R2SP70A3, R7SP70A3 or Ad3EGFP were immobilized in the wells of ELISA plates and incubated with anti-SP70-GST antibody diluted at 1:250. The binding was detected with an HRP-conjugated secondary antibody. (C) In the assay $5 \times 10^8$ VPs/well of R1SP70A3, R2SP70A3, R7SP70A3, or Ad3EGFP were adsorbed on ELISA plates followed by varying dilutions of control GST antiserum. Data are shown as mean ± SD for triplicate wells.

doi:10.1371/journal.pone.0041381.g003
neutralizing EV71 were determined as the dilutions with complete protection from CPE in in vitro micro-neutralization assays (Fig. 6). The titers of the antisera obtained from heat-inactivated EV71, R1SP70A3-, R2SP70A3-, R7SP70A3- or SP70-GST-immunized mice were 128, 128, 64, 32 and 32 respectively. Antiserum from the Ad3EGFP-immunized mice did not confer any protection to Vero cells from CPE. Mice which were not infected did not show any sign of distress and all of them survived. Hence, these data demonstrated that the modified viruses R1SP70A3, R2SP70A3, and R7SP70A3 elicited anti-EV71 neutralizing antibodies. To determine the lethal viral dosage, groups of mice on day 1 after birth were infected intraperitoneally with different doses of EV71-08-02, ranging from 10 TCID50 to 1000 TCID50 per mouse. With an infective dose of 1000 TCID50 or 100 TCID50 virus, all mice died in two weeks post-infection, whereas a 10% survival rate was observed by day 21 post-infection for those mice infected with a reduced dosage of 10 TCID50 per mouse (Fig. 7A). 100%, 70%, 60%, 20%, and 10% survival rates (n = 10 each group) were observed by day 21 post-infection for groups of EV71-infected suckling mice that received the anti-EV71, anti-R1SP70A3, anti-R2SP70A3, anti-R7SP70A3 and anti-SP70-GST antiserum respectively, whereas EV71-infected suckling mice which did not receive any antiserum and those which received antiserum from Ad3EGFP-immunized mice did not survive by day 16 post-infection (Fig. 7A). Compared with the group infected with EV71-1000TCID50 without antiserum, significant protective effects were observed for the groups that received anti-heat-inactivated EV71 (P<0.0001), anti-R1SP70A3 (P = 0.0011), anti-R2SP70A3 (P = 0.00021) and anti-R7SP70A3 antiserum (P = 0.0297). Injection with anti-EV71 (P<0.001), anti-R1SP70A3 (P = 0.0012) and anti-R2SP70A3 (P = 0.0042) antiserum significantly increased the survival rate of EV71-infected suckling mice compared with Ad3EGFP antiserum. The body weights of mice that were protected against EV71 infectivity rose steadily up to an average of approximately 10.7 g at day 21 post-infection. At day 9 post-infection, they weighed 6.2 g on average when compared with unprotected mice that had an average body weight of 2.1 g before they died or were humanely euthanized (Fig. 7B).

The vaccine candidates were also evaluated by challenging the neonatal mice born to immunized mother dams with lethal doses of EV71 (Fig. 8A). The NAb titers of sera from the immunized mother mice at 6 week after the first injection were determined (Fig. 8B). No mice in the control groups receiving Ad3EGFP or only PBS survived by day 15 after challenge with a dose of 1000TCID50 EV71. In contrast, the survival rates by day 15 post-infection were 58.3% (7/12), 54.5% (6/11), 16.7% (4/14), 8.3% (1/12), and 90.9% (10/11) for the groups of which the mother dams were immunized with R1SP70A3, R2SP70A3, R7SP70A3, SP70-GST and heat-inactivated EV71, respectively (Fig. 8C). Compared with the group receiving only PBS, significant protective effects were observed for the groups that received R1SP70A3 (P = 0.0024), R2SP70A3 (P = 0.0178), R7SP70A3 (P = 0.0315) and heat-inactivated EV71 (P<0.001). The higher protection for the groups that received R1SP70A3 (P = 0.007), R2SP70A3 (P = 0.037) than Ad3EGFP demonstrated that R1SP70A3 or R2SP70A3 immunization conferred protection that was passed from the mother mice to the neonatal mice. These data indicated that the antibodies elicited by hexon-modified Ad5 conferred effective protection against lethal EV71 challenge.

### Discussion

The definition of HVRs used in the study is based on analysis performed by Crawford-Miksa and Rux et al. [33,34]. By the web-FASTA tool of the PDB the chimpanzee adenovirus 68 (AdC68) hexon (PDB code: 2obe) at 2.1 Å resolution exhibited the highest degree of homology with the Ad3-gz01 hexon. Pichla-Golland et al. have more precisely defined the five exposed surface loop regions based on the crystal structure of AdC68 hexon [35]. Yuan et al. also predicted five surface epitope polypeptide segments in HA3-Harbin04B hexon by molecular modeling [36]. The five loops are located in HVRI, HVRII, HVRIV, HVRV5, and HVRV7 respectively. In this study, we found that the SP70 peptide could be genetically inserted into HVRI, HVRII, and HVRV5 regions of the Ad3 hexon without affecting virus formation and virion stability. However, the SP70 peptide inserted into HVRI or HVRV5 was affecting virus assembly or stability. The SP70 epitopes incorporated in HVRI, HVRII, and HVRV7 appeared to be exposed on the virion surface as assessed by ELISA with purified whole virion (Fig. 3). These results indicate that HVRI, HVRII, and HVRV7 of Ad3 hexon are suitable sites for antigen incorporation and display, since most peptide epitopes are between 6 and 14 amino acids in length. However, HVRII and HVRV5 of Ad5 vector are considered as the most flexible with respect to peptide or antigen incorporation [24,37]. McConnell et al. also demonstrated that HVRV5 of Ad5 can accommodate a peptide of up to 36 amino acids without adversely affecting virus infectivity, growth, or stability [23,24]. The first possible reason may be that some amino acids in the replaced residue of HVRV5 were indispensable to Ad3 hexon. Although the HVRV4 loop is exposed on the surface of Ad3 hexon, it is located on the side, and may be involved in protein interactions in the intact virion (the molecular model of Ad3-gz01 hexon, Fig. 9). It is necessary to further investigate which amino acids of the HVRV5 and HVRV4 regions of Ad3 hexon could be deleted without affecting virion formation.

Anti-SP70 humoral responses could be evidently boosted after homologous Ad vector administration (Fig. 4C). In contrast, the transgene production EGFP-specific antibody responses were noticeably inhibited after two injections (Fig. 4F). These data indicate the advantage of the antigen capsid incorporation approach which is viable even in individuals with preexisting immunity to adenovirus. These are consistent with previous Ad5-based work [25,38,39]. Anti-vector immunity represents a key limitation of current Ad5 vectors based on gene transfer, because boosting against transfer gene production is ineffective if immunity against the Ad vector was present [29]. Shiratsuchi et al. [28] found that replacing Ad5 vector HRV1 with a malaria B cell epitope improved immunogenicity and circumvented preexisting immunity to adenovirus in mice. But we have an interesting finding that the peptide SP70 antiserum efficiently neutralized
R1SP70A3, R2SP70A3, R7SP70A3 with a similar titer (Table 1). The data suggest that preexisting immunity to the foreign peptide incorporated in hexon should be taken into account which may inhibit transgene expression of gene transfer-based Ad vectors. It is a very interesting finding that the dominant SP70-specific IgG subtypes varied among the sera from mice immunized with rAds displaying SP70 in different HVRs (Fig. 4D). Continuous B cell stimulation by the antigen and maturation of high-affinity antibodies depend on the presence of T helper cells via the presentation of related peptides to the B cells [14]. This skewing toward Th1-type or Th2-type cellular immunity may account for the distribution of anti-Sp70 IgG isotypes. In mice, IgG1 is indicative of a Th2-type response, whereas IgG2a and IgG2b are predominantly produced during a Th1 response. It suggests that the incorporation of foreign epitope into hexon may impact the cellular immune response to rAds, which may in part explain the
Figure 5. SP70-specific IL-4 and IFN-γ responses after immunization with the hexon-modified Ad3. Spleens were harvested from BALB/c mice (n = 2 each group) immunized with R1SP70A3, R2SP70A3, R7SP70A3, heat-inactivated EV71 or PBS on day 5 after the third injection. Lymphocytes were isolated from spleens by density gradient centrifugation and IL-4 and IFN-γ responses after in vitro stimulation with either SP70 or GFP protein were measured by ELISPOT analysis. Shown are data for the number of spot-forming cells per 1 × 10⁵ splenocytes after in vitro stimulation by subtracting the number of spots formed by unstimulated cells. Data represent the mean ± SD of the mean of cells of each mouse plated in triplicate from one experiment representative of two separate experiments.

doi:10.1371/journal.pone.0041381.g005

Figure 6. In vitro neutralization against EV71-08-02 strain. Two-fold serial dilutions of each antiserum collected at 8 week were incubated together with 1000 TCID₅₀ of EV71-08-02 virus at 37 °C for 1 h before added to Vero cells in 96-well plates. After incubation for 48 h at 37 °C, titers from triplicate wells were read as the highest dilution of serum that completely protected cells from CPE. doi:10.1371/journal.pone.0041381.g006

In conclusion, we have successfully incorporated a 15 amino acid linear neutralizing epitope SP70 derived from EV71 into the Ad vector. It is likely that the SP70 epitope inserted into HVR1 of Ad3 hexon may be presenting in the more similar conformation to that within the context of an EV71 virion. The nature of epitopes and the precise sites of insertion could account for the observed difference [19,25].

In recent years, various types of experimental vaccines against EV71 have been investigated, including heat-inactivated or formaldehyde-inactivated whole virion, live attenuated virions, virus-like particles, recombinant VP1 protein, DNA vaccine and peptide-based vaccine targeting the neutralizing domain [41,42,43,44,45,46]. Four strong cross-reactivity inducing peptides between EV71 and human brain tissue were identified and two of them locate at VP2 and VP1, which may be responsible for the possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were secreted were not found in either rAds- or EV71 virions-immunized mice could be explained by two possibilities. First, it is possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were identified did not find T-cell epitope in the region of SP70 [40]. Second, there may be a T cell epitope, but the responses elicited by it were too weak to be distinguished from background due to the sensitivity of the ELISPOT method used.

In recent years, various types of experimental vaccines against EV71 have been investigated, including heat-inactivated or formaldehyde-inactivated whole virion, live attenuated virions, virus-like particles, recombinant VP1 protein, DNA vaccine and peptide-based vaccine targeting the neutralizing domain [41,42,43,44,45,46]. Four strong cross-reactivity inducing peptides between EV71 and human brain tissue were identified and two of them locate at VP2 and VP1, which may be responsible for the difference of NAb titers and protection efficacy against EV71 between R1SP70A3, R2SP70A3 and R7SP70A3. These may be a reflection of the Ad3 hexon T-cell epitopes or the adjuvant effect of the Ad vector. The finding that SP70-specific IL-4- or IFN-γ-secreting cells were not found in either rAds- or EV71 virions-immunized mice could be explained by two possibilities. First, it is possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were identified did not find T-cell epitope in the region of SP70 [40]. Second, there may be a T cell epitope, but the responses elicited by it were too weak to be distinguished from background due to the sensitivity of the ELISPOT method used.

In recent years, various types of experimental vaccines against EV71 have been investigated, including heat-inactivated or formaldehyde-inactivated whole virion, live attenuated virions, virus-like particles, recombinant VP1 protein, DNA vaccine and peptide-based vaccine targeting the neutralizing domain [41,42,43,44,45,46]. Four strong cross-reactivity inducing peptides between EV71 and human brain tissue were identified and two of them locate at VP2 and VP1, which may be responsible for the difference of NAb titers and protection efficacy against EV71 between R1SP70A3, R2SP70A3 and R7SP70A3. These may be a reflection of the Ad3 hexon T-cell epitopes or the adjuvant effect of the Ad vector. The finding that SP70-specific IL-4- or IFN-γ-secreting cells were not found in either rAds- or EV71 virions-immunized mice could be explained by two possibilities. First, it is possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were identified did not find T-cell epitope in the region of SP70 [40]. Second, there may be a T cell epitope, but the responses elicited by it were too weak to be distinguished from background due to the sensitivity of the ELISPOT method used.

In recent years, various types of experimental vaccines against EV71 have been investigated, including heat-inactivated or formaldehyde-inactivated whole virion, live attenuated virions, virus-like particles, recombinant VP1 protein, DNA vaccine and peptide-based vaccine targeting the neutralizing domain [41,42,43,44,45,46]. Four strong cross-reactivity inducing peptides between EV71 and human brain tissue were identified and two of them locate at VP2 and VP1, which may be responsible for the difference of NAb titers and protection efficacy against EV71 between R1SP70A3, R2SP70A3 and R7SP70A3. These may be a reflection of the Ad3 hexon T-cell epitopes or the adjuvant effect of the Ad vector. The finding that SP70-specific IL-4- or IFN-γ-secreting cells were not found in either rAds- or EV71 virions-immunized mice could be explained by two possibilities. First, it is possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were identified did not find T-cell epitope in the region of SP70 [40]. Second, there may be a T cell epitope, but the responses elicited by it were too weak to be distinguished from background due to the sensitivity of the ELISPOT method used.

In recent years, various types of experimental vaccines against EV71 have been investigated, including heat-inactivated or formaldehyde-inactivated whole virion, live attenuated virions, virus-like particles, recombinant VP1 protein, DNA vaccine and peptide-based vaccine targeting the neutralizing domain [41,42,43,44,45,46]. Four strong cross-reactivity inducing peptides between EV71 and human brain tissue were identified and two of them locate at VP2 and VP1, which may be responsible for the difference of NAb titers and protection efficacy against EV71 between R1SP70A3, R2SP70A3 and R7SP70A3. These may be a reflection of the Ad3 hexon T-cell epitopes or the adjuvant effect of the Ad vector. The finding that SP70-specific IL-4- or IFN-γ-secreting cells were not found in either rAds- or EV71 virions-immunized mice could be explained by two possibilities. First, it is possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were identified did not find T-cell epitope in the region of SP70 [40]. Second, there may be a T cell epitope, but the responses elicited by it were too weak to be distinguished from background due to the sensitivity of the ELISPOT method used.

In recent years, various types of experimental vaccines against EV71 have been investigated, including heat-inactivated or formaldehyde-inactivated whole virion, live attenuated virions, virus-like particles, recombinant VP1 protein, DNA vaccine and peptide-based vaccine targeting the neutralizing domain [41,42,43,44,45,46]. Four strong cross-reactivity inducing peptides between EV71 and human brain tissue were identified and two of them locate at VP2 and VP1, which may be responsible for the difference of NAb titers and protection efficacy against EV71 between R1SP70A3, R2SP70A3 and R7SP70A3. These may be a reflection of the Ad3 hexon T-cell epitopes or the adjuvant effect of the Ad vector. The finding that SP70-specific IL-4- or IFN-γ-secreting cells were not found in either rAds- or EV71 virions-immunized mice could be explained by two possibilities. First, it is possible that SP70 may not contain a T cell epitope. The previous study in which human CD4+ T-cell epitopes from VP1 of EV71 were identified did not find T-cell epitope in the region of SP70 [40]. Second, there may be a T cell epitope, but the responses elicited by it were too weak to be distinguished from background due to the sensitivity of the ELISPOT method used.
out to create novel multivalent Ad3 vaccine vectors presenting several linear T-cell or B-cell epitopes derived from EV71 on the same virion that would yield optimal vaccine efficacy.

**Materials and Methods**

**Cells, Virus Strains, and Vectors**
A sub-cell line of AD293 and HEp-2 cells (human Epidermoid carcinoma cell line), Vero cells (African green monkey kidney cell lines) purchased from ATCC were kept in our lab and cultured in DMEM supplemented with 10% FBS and antibiotics [29,54]. The E3-defective adenovirus type 3 replication-competent plasmid, pBRAdV3dE3egfp (pAd3egf) with enhanced green fluorescence protein (EGFP) as report gene, corresponding virus Ad3/H3 (Ad3EGFP) and the shuttle vector pBRH3S were provided by Qiwei Zhang or constructed before [29,54]. The EV71-08-02 strain (GenBank No. FJ360545), a clinical isolate of EV71 virus from a child with HFMD in 2008 in Guangzhou of southern China was obtained from Guangzhou Woman and Children’s Medical Center and determined to be genotype C4 by genome sequence analysis. EV71 virus stock was collected from infected Vero cells 3 days post-infection at 37°C. The virus from the cell culture was purified by precipitation with 7% polyethylene glycol 8000 and then centrifuged on a 30% sucrose cushion at 25,000 g for 4 h. The virus titer was determined as TCID 50 in Vero cells, based on typical cytopathic effect (CPE) produced by viral infection.

**Construction of Recombinant Adenoviral Vectors**

According to the alignment with amino acid sequences of AdC68 and Ad3-Harbin04B strain hexons, it is highly likely that HVR1, HVR2, HVR4, HVR5, and HVR7 of Ad3/H3 hexon extrude from the capsid surface and stretch to the external environment (Fig. 10A). The amino acid residues of SP70 containing 208–222 of VP1 protein are highly conserved amongst the VP1 sequences of EV71 strains from various subgenogroups [9,10]. The EV71 neutralizing epitope SP70 was molecularly incorporated into these hexon HVRs at positions marked in Fig. 10B.

To accomplish these genetic modifications, we first obtained hexon fragments containing sequences encoding the SP70 epitope in different HVRs via overlapping PCR. For instance, to obtain a SP70 insertion in HVR1 (R1SP70), using Ad3 hexon as the template, we first amplified fragment 1L with primers HexU and hr1-sp70R, and fragment 1R with primers HexD and hr1-sp70U (shown in Table 2). After purification of fragments 1L and 1R, 50 ng of each fragment was mixed and used as the template and primers for 6 cycles of amplification, resulting in insertion of sequences encoding SP70 and the spacers in HVR1. Next, primers HexU and HexD were added into the tubes to amplify the

---

**Figure 7. Passive protection against lethal EV71 strain challenge in suckling mice.** (A) Groups of mice (n = 10 each group) at day 1 after birth were intraperitoneally injected with a lethal dose of 1000 TCID50 EV71 per mouse and 20 μl of heat-treated (56°C, 30 min) antiserum from EV71-, R1SP70A3-, R2SP70A3-, R7SP70A3- or Ad3EGFP-immunized mice. Suckling mice in the control group were not given any antiserum at all. Mice were monitored each day for body weight gain/loss and the occurrence of mortality until three weeks post-infection and mice that were failure in gaining weight or met end point criteria were humanely euthanized to minimize pain and suffering. Injection with EV71 (P < 0.001), R1SP70A3 (P = 0.0012) and R2SP70A3 (P = 0.0042) antiserum significantly increased the survival rate compared with Ad3EGFP. (B) Monitoring of body weight gain/loss in suckling Balb/c mice after EV71 challenge. Error bars represent the standard errors of the means for all samples available of each group at that time point.

**PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e41381**
with the group injected with PBS.

1-day-old neonatal BALB/c mice (n = 11 to 14) born to immunized dams were inoculated by i.p. with EV71 (1000 TCID50 per mouse) after fasting for 1 h before added to Vero cells in 96-well plates. After incubation for 48 h at 37°C, titers from triplicate wells were read as the highest dilution of serum that completely protected cells from CPE. (C) Neutralization against EV71-08-02 strain. In vitro virus at 37°C for 1 h before added to Vero cells in 96-well plates. After incubation for 48 h at 37°C, titers from triplicate wells were read as the highest dilution of serum that completely protected cells from CPE.

Figure 8. Protection to newborn mice against lethal EV71 challenge through maternally transferred antibodies. (A) Immunization timeline showing when immunizations were performed. Sera were collected for antibodies assay and mice were allowed to mate with male mice. (B) In vitro neutralization against EV71-08-02 strain. Two-fold serial dilutions of each antisera collected at 6 week from mother mice were incubated together with 1000 TCID50 of EV71-08-02 virus at 37°C for 4 h. Mice were monitored each day for body weight gain/loss and the occurrence of mortality until three weeks post-infection and mice that were failure in gaining weight or met end point criteria were humanely euthanized to minimize pain and suffering. Effective protection were observed for the groups of which the mother mice were injected with R1SP70A3 (P = 0.0024), R2SP70A3 (P = 0.0178), R7SP70A3 (P = 0.0315) and heat-inactivated EV71 (P = 0.001) compared with the group injected with PBS. doi:10.1371/journal.pone.0041381.g008

Growth Characteristics and Virus Thermostability

Growth curves were generated by infecting HEp-2 cells in 24-well plates with Ads at 5 VPs/cell in 500 μl growth medium containing 2% FBS. The infected cells were harvested with medium at various time points post-infection for 4 days. The collected cells together with the medium were lysed by three freeze–thaw cycles, and subjected to centrifugation at 10000 g for 30 min at 4°C for cell debris removal. The number of infectious particles in each sample was determined by fluorescent focus assay at 40 h post-infection, and plotted as growth curves. To test the heat stability of the hexon-modified adeno-virus, the viruses were incubated at 45°C for 0, 5, 10, 20, 40 or 60 min in growth medium containing 2% FBS before infecting HEp-2 cells. Then the infectivity remaining at each time point was re-determined by fluorescent focus assay at 48 h post-infection.

For gene transfer efficacy assay, HEp-2 cells were seeded into 96-well NUNC Optical bottom plates (ThermoFisher Scientific) and infected with Ads at multiplicities of infection (MOI) of 1, 5, 25, and 125 VPs/cell, and cultured in RPMI Medium 1640 without phenol red and without serum for 48 h. The fluorescence was measured with a Varioskan Flash Multimode Reader (Thermo Scientific) by exciting at 488 nm and recording the emitted light at 507 nm. Background fluorescence was equalized to wells only containing cells.

Peptide Synthesis and Production of Recombinant SP70 Fusion Peptide

The peptide sp70 was synthesized by Jetway Co. Ltd (Guangzhou, China). The peptide was purified by high-performance liquid chromatography to 85% purity, and the identity of the peptide was confirmed by mass spectrometry analysis. SP70 was dissolved in water to 1 mg/ml and stored at −80°C in aliquots to avoid repetitive freeze-thaw cycles.
To produce a recombinant SP70 fusion peptide with an N-terminal GST tag, the 126 bp of the fragment containing SP70 gene was amplified with primers E592u (5'-CGT GAA TTC GCG AGT GCT TAT CAA TGG-3') and E696r (5'-CGA TGC GGC CGC GTT CAT CAT GTT GTT-3') by RT-PCR using EV71 genome as template. Then the fragment was cloned into the expression vector pGEX-4T-3 with an N-terminal GST tag after EcoRI- and NotI- double-digestion. Then the recombinant vector pGEX-SP70 was transformed into *Escherichia coli* BL21(DE3). The recombinant fusion peptide SP70-GST was purified by affinity chromatography using GST-Bind Resin (Novagen, USA) from a single transformant under native conditions. The control protein GST was purified at the same condition.

**Mouse Immunization**

Female Balb/c mice aged 4–6 weeks were used in the immunization experiments. Mice in groups of 5 were immunized with $5 \times 10^9$ VP, recombinant viruses Ad3EGFP, R1SP70A3, R2SP70A3, or R7SP70A3 by intramuscular (i.m.) injection, heat-inactivated EV71 strain (10 µg total protein), 50 µg SP70-GST or GST protein and synthesized SP70 peptide with complete adjuvant by intraperitoneal (i.p.) inoculation, and phosphate-buffered saline (PBS) served as the negative controls. Three booster doses were given at 2 weeks intervals with the same dose of antigen. Immune sera were collected from anesthetized mice before each immunization and kept frozen for serology tests. Blood was collected from anesthetized mice via the orbit at ten days after the final immunization and transferred to a microfuge tube. Tubes were centrifuged and sera were removed and frozen at $-80 \pm 5^\circ$C for in vitro neutralization assay and passive protection experiment against lethal EV71 strain challenge in suckling mice.

**Western Blot Analysis**

To analyze SP70 presentation on selected vectors, the total proteins of purified EV71 or recombinant adenoviruses cultures were separated in 10% SDS polyacrylamide gels. The proteins were transferred onto PVDF membranes using a wet blotter. The membranes were blocked with 5% skim-milk in PBS and then incubated with the anti-SP70-GST serum (1:250), washed and exposed to a 1:10000 dilution of goat anti-mouse IgG (H + L)-HRP conjugate affinity-purified secondary antibody (Bio-Rad). The blot was developed using Immobilon Western chemiluminescence HRP substrate (Millipore).

Total viral proteins of the EV71 strain and purified SP70-GST were used to study immunoreactivity of the antisera of mice immunized with R1SP70A3, R2SP70A3, and R7SP70A3. Briefly, proteins were separated in 12% SDS polyacrylamide gels, and...
transferred onto PVDF membranes. After blocking with 5% skim-milk, the membranes were incubated with the hyperimmune anti-rAds sera, washed and exposed to a 1:10000 dilution of secondary Ab (Bio-Rad). The blot was developed using the substrate described above.

**ELISA**

In order to determine if the SP70 peptide was surface exposed on the rAds virion, whole virus ELISA was performed according to the method previously described by Matthews et al. (30). Briefly, 96-well plates (Nunc Maxisorp) coated overnight with different amounts of viruses ranging from $10^7$ to $10^{10}$ VPs in 100 μl of 100 mM carbonate buffer (pH 9.6) per well at 4°C were washed with 0.05% Tween 20 in Phosphate-buffered saline (PBST) and blocked with 2% bovine serum albumin (BSA) in PBST. Then the plates were incubated with anti-SP70-GST antibody for 1 h at 37°C. The plates were washed three times with PBST and incubated for 1 h with a 1:8000 dilution of secondary Ab. The plates were washed four times, developed with tetramethylbenzidine (TMB) substrate, stopped with 2 M H2SO4, and analyzed at

---

**Figure 10. Diagram of the SP70 incorporation sites in Ad3 hexon.** (A) Partial amino acid sequence alignments of Ad3-gz01 and AdC68, Ad3-Harbin04B hexons, showing residues 133–490 of Ad3-gz01 hexon. The potential surface epitope polypeptide segments are colored. (B) Amino acid residues of the SP70 motif marked in red were incorporated into HVRs of Ad3 hexon. The numbers show the positions of the amino acid residues in the Ad3 hexon.

doi:10.1371/journal.pone.0041381.g010
Table 2. Primers used to incorporate the SP70 epitope into the HVRs of the Ad3 hexon.

| Name     | Sequence          |
|----------|-------------------|
| HexU     | 5′-CCCATGATGATGCCCAGATGGA-3′ |
| HexD     | 5′-CGGGATACCTCCAAGACTGGC-3′ |
| hr1-sp70U| 5′-GTTAACAGTATCCCATCGGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr1-sp70R| 5′-GGTTGAGATATCCCATCGGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr2-sp70U| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr2-sp70R| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr4-sp70U| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr4-sp70R| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr5-sp70U| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr5-sp70R| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr7-sp70U| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |
| hr7-sp70R| 5′-GATCTGGAACCACACACAGGAAAGATCTTGGAATATATACCACCAAAACACATTTGGCC-3′ |

*Underlined letters represent the sequences encoding the SP70 epitope.

doi:10.1371/journal.pone.0041381.t002

In vitro Neutralization

The presence of neutralizing antibodies against EV71 was assayed in an in vivo microneutralization test with Vero cells. Aliquots of mouse sera were incubated at 36°C for 30 min prior to use. Briefly, 50 μl of two-fold serially diluted sera were mixed with equal volumes of 1000 TCID₅₀ of virus and incubated at 37°C for 1 h. Then the mixtures were adsorbed onto 96-well microtiter plates seeded the previous day with Vero cells. After incubation for 48 h at 37°C, titers from triplicate wells were read as the highest dilution at which the OD₅₆₀ was at least 0.1 above that of wells receiving no serum. Wells receiving no serum always had an OD₅₆₀ of <0.1.

ELISPOT

For assessment of the SP70-specific cellular immune response, Balb/c mice were immunized intramuscularly with 5×10⁵ VP recombinant viruses R1SP70A3, R2SP70A3, or R7SP70A3. Two booster doses were given at 2 weeks intervals. Heat-inactivated EV71 strain (10 μg total protein) and PBS (naive) with adjuvant were injected into mice by i.p. served as the controls. The frequency of antigen-specific T lymphocytes was determined by IFN-γ and IL-4 ELISPOT assays 5 days after the third injection. The spleens of two mice from each group were collected and homogenized in a density gradient of 1.081 g/mL EZ-Sep™ medium (DAKEWE Biotech), then the cell suspensions were transferred into 13 ml centrifugal tubes and covered with 200 μl RPMI-1640 medium, centrifuged at 800 x g for 30 min at room temperature. The mononuclear-cell-enchired fraction was collected, then washed once and diluted to the desired concentration with RPMI-1640 medium. 5×10⁵ cells per well were cultured in Lympho-Spot™ serum free medium universal (DAKEWE Biotech) and stimulated with 20 μg/ml SP70 peptide or 10μg/ml GFP protein, or left unstimulated as control for 24 hr in 96-well plate that had been coated with capture antibodies to either mouse IFN-γ or IL-4. The spots were counted using an ELISPOT reader. The number of spot-forming cells for each stimulated sample was determined by subtracting the number of spots formed by unstimulated cells from the same mice. All samples were run in triplicate.

In vivo Protection against Lethal Enterovirus 71 Infection

EV71 infection caused no apparent clinical symptoms in adult Balb/c. For the passive protection study, neonatal Balb/c mice were used as described by Foo et al. [10]. The sera from mice on day 10 after the 4th immunization were collected as described above (Fig. 4A). Groups of neonatal mice (n = 10 each group) at

450 nm with ELISA plate reader (Thermo Scientific Multiskan MK3).

For the anti-SPT0 humoral responses, ELISA plates were coated with 0.1 μg of the synthetic SP70 peptide or recombinant SP70-GST protein in 100 μl of 50 mM carbonate buffer (pH 9.6) per well. Plates were washed and then blocked with 2% BSA/PBST. After incubation with serially diluted sera for 1 h at 37°C, the plates were washed three times with PBST and incubated for 1 h with a 1:8000 dilution of peroxidase-conjugated Affinipure goat anti-mouse sub-types specific antibody (ProteinTech). ELISAs were developed with TMB. In order to determine SP70 isotype-specific reactivity of the mice anti-sera, ELISA plates were coated with 0.1 μg of the synthetic SP70 peptide in 100 μl of 50 mM carbonate buffer (pH 9.6) per well and then blocked with 2% BSA/PBST. After incubation with serially diluted sera for 1 h at 37°C, the plates were washed three times with PBST and incubated for 1 h with a 1:2000 dilution of peroxidase-conjugated Affinipure goat anti-mouse sub-types specific antibody (ProteinTech). The presence of neutralizing antibodies against EV71 was assayed in an in vitro microneutralization test with Vero cells. Aliquots of mice sera were incubated at 36°C for 30 min prior to use. Briefly, 50 μl of two-fold serially diluted sera were mixed with equal volumes of 1000 TCID₅₀ of virus and incubated at 37°C for 1 h. Then the mixtures were adsorbed onto 96-well microtiter plates seeded the previous day with Vero cells. After incubation for 48 h at 37°C, titers from triplicate wells were read as the highest dilution of sera that inhibited virus growth.

For the in vitro Ad neutralization experiments, the antisera from mice immunized with Ad3EGFP were 2-fold serially diluted in DMEM, and 50 μl aliquots of each dilution were mixed with 50 μl rAds of 2×10⁹ VPs. The antibody-virus mixtures were incubated for 1 h at 37°C and then transferred to 96-well plates containing 50-95% confluent monolayers of Hep-2 cells. Monolayers were cultured in RPMI Medium 1640 (GIBCO) without phenol red and serum for 72 h. Infected cells were analyzed with a Varioskan Flash Multimode Reader (Thermo Scientific) to measure the EGFP expression. The serum neutralization titer was defined as the reciprocal of the serum dilution that inhibited 90% of the EGFP expression.

ELISPOT

For assessment of the SP70-specific cellular immune response, Balb/c mice were immunized intramuscularly with 5×10⁵ VP recombinant viruses R1SP70A3, R2SP70A3, or R7SP70A3. Two booster doses were given at 2 weeks intervals. Heat-inactivated EV71 strain (10 μg total protein) and PBS (naive) with adjuvant were injected into mice by i.p. served as the controls. The frequency of antigen-specific T lymphocytes was determined by IFN-γ and IL-4 ELISPOT assays 5 days after the third injection. The spleens of two mice from each group were collected and homogenized in a density gradient of 1.081 g/mL EZ-Sep™ medium (DAKEWE Biotech), then the cell suspensions were transferred into 13 ml centrifugal tubes and covered with 200 μl RPMI-1640 medium, centrifuged at 800 x g for 30 min at room temperature. The mononuclear-cell-enchired fraction was collected, then washed once and diluted to the desired concentration with RPMI-1640 medium. 5×10⁵ cells per well were cultured in Lympho-Spot™ serum free medium universal (DAKEWE Biotech) and stimulated with 20 μg/ml SP70 peptide or 10μg/ml GFP protein, or left unstimulated as control for 24 hr in 96-well plate that had been coated with capture antibodies to either mouse IFN-γ or IL-4. The spots were counted using an ELISPOT reader. The number of spot-forming cells for each stimulated sample was determined by subtracting the number of spots formed by unstimulated cells from the same mice. All samples were run in triplicate.

In vivo Protection against Lethal Enterovirus 71 Infection

EV71 infection caused no apparent clinical symptoms in adult Balb/c. For the passive protection study, neonatal Balb/c mice were used as described by Foo et al. [10]. The sera from mice on day 10 after the 4th immunization were collected as described above (Fig. 4A). Groups of neonatal mice (n = 10 each group) at
day 1 after birth were injected intraperitoneally with 10 μl of EV71 (1000 TCID50 per mouse) and with 20 μl of heat-treated (56°C, 30 min) mice immune sera one hour later. Suckling mice (n = 10 each group) from control groups were either given anti-Ad3EGFP serum or not given any antiserum at all. Mice were monitored each day for body weight gain/loss and the occurrence of mortality until three weeks post-infection and mice that were failure in gaining weight or met end point criteria were humanely euthanized to minimize pain and suffering.

Protective effect of vaccine candidates against EV71 infection was also evaluated in newborn Balb/c mice with the transferred maternal antibody from immunized mother mice. Female Balb/c mice aged 6 weeks were immunized with 1×1011 VPs recombinant viruses Ad3EGFP, R15SP70A3, R2SP70A3, or R7SP70A3 by i.m. injection, heat-inactivated EV71 strain (10 μg total protein), 50 μg SP70-GST protein with adjuvant by i.p. inoculation, and phosphate-buffered saline (PBS). Animal were boosted twice after 2 weeks and 4 weeks of the first immunization. The sera were collected from the mother mice 2 weeks after the third injection and then sent to in vitro NAbs titer analysis (Fig. 8A). The female mice were allowed to mate at 5 weeks after the first injection (Fig. 8A). For EV71 challenge, groups of 1-day-old pups born to the immunized dams were inoculated by i.p. with EV71 (1000 TCID50 per mouse) after fasting for 4 h. Mice were monitored each day for body weight gain/loss and the occurrence of mortality until three weeks post-infection and mice that were failure in gaining weight or met end point criteria were humanely euthanized to minimize pain and suffering.

Statistical Analysis

The data are presented as the mean ± the standard error. Statistical significance was determined using Prism 5.0 software.

References

1. Wong KT, Lam LC, Lam SK (2000) Enterovirus 71 infection and neurologic complications. N Engl J Med 342: 356–358.
2. McMinn P, Stratov I, Nagarajan L, Davis S (2001) Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 32: 236–242.
3. Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY (2007) Epidemiologic features of hand-foot-mouth disease and handpoxing caused by enterovirus 71 in Taiwan, 1996–2005. Pediatrics 120: e244–252.
4. Ho M, Chen EK, Hsu KH, Tsai SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929–935.
5. Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al. (2009) Enterovirus 71 outbreak in the People’s Republic of China in 2008. J Clin Microbiol 47: 2351–2352.
6. Fujimoto T, Chihabira M, Yoshida S, Ebida H, Hasegawa A, et al. (2002) Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 46: 621–627.
7. Gilbert GL, Dickson KE, Waters MJ, Kenettt ML, Land SA, et al. (1998) Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 7: 404–408.
8. Zhang D, Lu J (2010) Enterovirus 71 vaccine: close but still far. Int J Infect Dis 14: 473–479.
9. FosDG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61–68.
10. FosDG, Alonso S, Chow VT, Poh CL (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299–1306.
11. Li X, Mao C, Ma S, Wang X, Sun Z, et al. (2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126–1129.
12. Sette A, Flakes J (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461–470.
13. Dudke NL, Prellmuter F, Aguilar MI, Croft NP, Purcell AW (2010) Epitope discovery and their use in peptide based vaccines. Curr Pharm Des 16: 3149–3157.
14. Purcell MW, McClayey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404–414.
15. Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5: 389–390.
16. Zhi Y, Farina JB, Meshack S, Santovenia A, Patel S, et al. (2010) Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine 37: 430–439.
17. Jones PR, Gabitzsch ES, Xu Y, Balint JP, Bonichich V, et al. (2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29: 7020–7026.
18. Matthews QL (2011) Capsid- incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm 8: 3–11.
19. Crompton J, Toogood CI, Wallis N, Hay RT (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75 (Pt 1): 133–139.
20. Manou H, Sakaki F, Kuraschi S, Tashiro K, Sueko K, et al. (2009) Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene Ther 16: 1050–1057.
21. Krause A, Jof JH, Hackett NR, Roelvink PW, Bruder JT, et al. (2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5525–5530.
22. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 414: 249–251.
23. McConnell MJ, Danthinne X, Imperiale MJ (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361–5370.
24. Wu H, Han T, Belousova N, Kraayk V, Kashentseva E, et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79: 3382–3390.
25. Matthews QL, Fatima A, Tang Y, Perry BA, Tsutata Y, et al. (2010) HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One 5: e11815.
26. Youal R, Toner T, Su Q, Chen M, Tang A, et al. (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13: 311–320.
27. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob. Gene Ther 16: 1050–1057.
and circumvents preexisting immunity to adenovirus in mice. J Clin Invest 120: 3688–3701.

29. Zhang Q, Su X, Seto D, Zheng BJ, Tian X, et al. (2009) Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine 27: 1145–1153.

30. Stone D, Liu Y, Li ZY, Tuve S, Strauss R, et al. (2007) Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol Ther 15: 2146–2153.

31. Short JJ, Vasa C, Holtermann MJ, Curiel DT, Pereboev A (2006) Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res 122: 144–153.

32. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, et al. (2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78: 4454–4462.

33. Crawford-Miksza L, Schnurr DP (1996) Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70: 1836–1844.

34. Rux JJ, Kiser PR, Burnett RM (2003) Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77: 9553–9566.

35. Pichla-Gollon SL, Drinker M, Zhou X, Xue F, Rux JJ, et al. (2007) Structure-based identification of a major neutralizing site in an adenovirus hexon. J Virol 81: 1680–1689.

36. Yuan X, Qu Z, Wu X, Wang Y, Liu L, et al. (2009) Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. Vaccine 27: 5103–5110.

37. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al. (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.

38. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an OprF epitope in the capsid. J Clin Invest 115: 1281–1289.

39. Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K (2011) Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine 29: 1463–1471.

40. Foo DG, Macary PA, Alonso S, Poh CL (2008) Identification of human enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 6: e20005.

41. Liu JN, Wang W, DuO JY, Hao Y, Ma CM, et al. (2010) Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28: 7444–7451.

42. Ong KC, Devi S, Gaedoa MJ, Wong KT (2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 84: 661–665.

43. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2001) Protection against leptal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 19: 895–904.

44. Chang YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against leptal challenge. Vaccine 26: 1855–1862.

45. Tung WS, Bakar SA, Sekawi Z, Rosh R (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.

46. Liu JN, Li WB, Ma CM, Lin SZ, et al. (2010) The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J 7: 47.

47. Yuan X, Qu Z, Wu X, Wang Y, Liu L, et al. (2009) Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein. Vaccine 27: 5103–5110.

48. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al. (2008) Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.

49. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an OprF epitope in the capsid. J Clin Invest 115: 1281–1289.

50. Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K (2011) Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid. Vaccine 29: 4360–4372.

51. Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, et al. (2004) Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol 85: 2981–2989.

52. Arevalo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, et al. (2009) Mucosal vaccination with a multicomponent adenovirus-vectorized vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunology & Medical Microbiology 55: 346–351.

53. Wang SM, Liu CC (2009) Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Antic Infect Ther 7: 735–742.

54. Solomon T, Lewdowie P, Ferrera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778–790.

55. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, et al. (2008) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7: 523–528.

56. Tian X, Su X, Li H, Li X, Zhou Z, et al. (2011) Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Res 160: 214–220.